Table 3.

Number of patients with ATTR-CM identified over time

Year	Newly included patients (n)	Patients with prevalent ATTR-CM* (n)	Population at risk	Prevalence per 100 000†
2008	96	96	9 256 347	1.0
2009	69	141	9 340 682	1.5
2010	74	183	9 415 570	1.9
2011	57	204	9 482 855	2.2
2012	97	259	9 555 893	2.7
2013	83	291	9 644 864	3.0
2014	92	332	9 747 355	3.4
2015	100	382	9 851 017	3.9
2016	122	443	9 995 153	4.4
2017	117	499	10 120 242	4.9
2018	87	510	10 230 185	5.0

*The sum of patients included in previous years and still alive and newly included patients that year. First year of patient inclusion is 2008.

†Calculated as number of patients with prevalent ATTR-CM per year divided by population at risk.

ATTR-CM, transthyretin amyloid cardiomyopathy.